Liquid Biopsy Allows Monitoring of COVID-19 Damage to Cells, Tissues, and Organs
|
By LabMedica International staff writers Posted on 09 Feb 2021 |
|
Image: Transmission electron microscope image showing SARS-CoV-2, the virus that causes COVID-19. Virus particles are shown emerging from the surface of cells cultured in the laboratory (Photo courtesy of US NIAID, via Wikimedia Commons)
A recent study presented results that point to the utility of exploiting cell-free DNA as an analyte to monitor the damage caused to cells, tissues, and organs by COVID-19.
While COVID-19 primarily affects the lungs, evidence of systemic disease with multi-organ involvement has emerged. In order to better understand this phenomenon, investigators at Cornell University (Ithaca, NY, USA) and colleagues in the United States and Canada developed a blood test to broadly quantify cell, tissue, and organ specific injury due to COVID-19.
For this study, the investigators employed a liquid biopsy method to conduct genome-wide methylation profiling of cell-free DNA in the blood plasma. They assessed the utility of this test to identify subjects with severe disease in two independent, longitudinal cohorts of hospitalized patients. Cell-free DNA profiling was performed on 104 plasma samples from 33 COVID-19 patients and compared to samples from patients with other viral infections and healthy controls.
The investigators reported finding evidence of injury to the lung and liver and involvement of red blood cell progenitors associated with severe COVID-19. Furthermore, a high concentration of cell-free DNA in the blood was itself a strong prognostic marker for severe COVID-19 cases.
“A lot of what we have learned about the involvement of the virus with different organs is from invasive biopsies, postmortem biopsies,” said senior author Dr. Iwijn De Vlaminck, assistant professor of biomedical engineering at Cornell University. “But a liquid biopsy is potentially very useful as a biological measurement, a way to study what is going on in patients who have different types of symptoms, for example. It could be used to assess disease severity and help stratify patients in the care system. It could also potentially be a surrogate biomarker that you could include in randomized controlled trials of various anti-COVID therapies and anti-virals.”
The cell-free DNA study was published in the January 16, 2021, online edition of the journal Cell Med.
Related Links:
Cornell University
While COVID-19 primarily affects the lungs, evidence of systemic disease with multi-organ involvement has emerged. In order to better understand this phenomenon, investigators at Cornell University (Ithaca, NY, USA) and colleagues in the United States and Canada developed a blood test to broadly quantify cell, tissue, and organ specific injury due to COVID-19.
For this study, the investigators employed a liquid biopsy method to conduct genome-wide methylation profiling of cell-free DNA in the blood plasma. They assessed the utility of this test to identify subjects with severe disease in two independent, longitudinal cohorts of hospitalized patients. Cell-free DNA profiling was performed on 104 plasma samples from 33 COVID-19 patients and compared to samples from patients with other viral infections and healthy controls.
The investigators reported finding evidence of injury to the lung and liver and involvement of red blood cell progenitors associated with severe COVID-19. Furthermore, a high concentration of cell-free DNA in the blood was itself a strong prognostic marker for severe COVID-19 cases.
“A lot of what we have learned about the involvement of the virus with different organs is from invasive biopsies, postmortem biopsies,” said senior author Dr. Iwijn De Vlaminck, assistant professor of biomedical engineering at Cornell University. “But a liquid biopsy is potentially very useful as a biological measurement, a way to study what is going on in patients who have different types of symptoms, for example. It could be used to assess disease severity and help stratify patients in the care system. It could also potentially be a surrogate biomarker that you could include in randomized controlled trials of various anti-COVID therapies and anti-virals.”
The cell-free DNA study was published in the January 16, 2021, online edition of the journal Cell Med.
Related Links:
Cornell University
Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
New
HPV Molecular Test
BD Onclarity HPV Assay
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read more
Hematology
view channel
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read more
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read more
Immunology
view channel
Combined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read more
Pathology
view channel
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more_image.png "Image: Through neoadjuvant therapy combining chemotherapy with immune checkpoint inhibitors (ICI) for 46 LAGC patients and single-cell transcriptome sequencing, researchers found that tumor cells in the treatment-sensitive group specifically upregulated MHC-II (tumor-specific major histocompatibility complex class II, tsMHC-II) molecules (photo courtesy of Science China Press)")
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read more
Technology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read more
Industry
view channel
Global Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more
